Información sobre riesgo, prevención, detección, síntomas, diagnosis, tratamiento y apoyo para el cáncer.
Información sobre el tratamiento del cáncer incluyendo quirúrgica, quimioterapia, radioterapia, estudios clínicos, terapia con protón, medicina complementaria avanzadas.
OncoLink se complace en ofrecer una amplia lista de lista completa de los agentes quimioterapéuticos más comúnmente usados??. Esta guía de referencia incluye información sobre la forma en que cada fármaco se administra, cómo funcionan, y los pacientes los efectos secundarios comunes pueden experimentar.
Maneras que los pacientes de cáncer y las personas que le cuidan puedan enfrentar el cáncer, los efectos secundarios, nutrición, cuestiones en general sobre el apoyo para el cáncer, duelo/decisiones sobre el termino de vida, y experiencias compartidas por sobrevivientes.
Librera OncoLink / Repaso de Diarios
Pamela K. Woodard, M.D., Farrokh Dehdasti, M.D., and Charles E. Putman, M.D.
Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 1 de noviembre del 2001
Reviewers: Leonard A. Farber, MD and John Chang, MD
Source: Oncology, March 1998, Volume 12, Number 3, 431-438
At present, the standard diagnostic imaging modalitiesfor detection of metastases to the lungs include the chest radiographand thoracic computed tomography (CT). Rates of detecting thoracicmetastases have great variability at autopsy. Early detectionof pulmonary metastases during a patient's clinical course mayultimately affect tumor staging and treatment planning. However,it is also important to avoid subjecting patients to unnecessaryprocedures on the basis of low likelihood of positive yield. For these reasons, it is reasonable to assess the utility of othermodalities that may be valuable in detecting metastases. Theseinclude positron emission tomography (PET) and magnetic resonanceimaging (MRI).
There are a variety of factors that may help determinewhich tests will be most useful in demonstrating pulmonary metastasesfrom extrathoracic primary tumors: mechanisms of hematogenoustumor spread, the likelihood of distant metastasis vs. spreadto nearby lymph nodes, and the probability of distant metastasiswith the presence of local invasion. Depending on the tumor typeand the extent of local disease, different radiologic modalitiesmay be necessary for optimal screening for detection of metastaticdisease.
Cancers That Metastasize to the Lung
Primary tumors that have a high propensity for pulmonary metastasesinclude melanomas, choriocarcinomas, sarcomas, and carcinomasof the head and neck, testis, and adrenal gland, as well as certaintypes of thyroid cancer. Primary tumors that are not as likelyto metastasize to the lung but are found in high prevalence inthe population include adenocarcinoma of the breast, colorectum,stomach, and pancreas.
Patterns of Metastases
Depending on the primary tumor type and location, the patternsof hematogenous spread follow a multi-step cascade process, thathelp explain the likelihood of metastasis to each organ system. The authors summarize this in a table, as shown below:
Pattern | Examples |
| Group I: Lungs as first site of metastasis | Sarcomas, melanomas, choriocarcinomas, thyroid carcinomas, adrenal gland tumors, testicular carcinomas, head and neck tumors |
| Group II: Metastasis to the lung only after initial seeding of liver | Adenocarinomas of the stomach, colon, and pancreas |
| Group III: Simultaneous seeding of multiple organs, including the lung | Transitional cell carcinoma (bladder, ureter), renal cell carcinoma , uterine and cervical cancers |
| Group IV: Metastasize first to bone; infrequently to lung | Prostate cancer |
| Group V: Complicated pattern of metastasis; first site may be the lung, liver, or bone | Breast cancer |
Standard Chest Radiograph: The standard PA and lateralchest radiograph is the most fundamental screening tool for pulmonarymetastatic disease. It may be used for staging and follow-up.
Thoracic CT: Chest CT scans, especially spiral techniques,are highly sensitive for the detection pulmonary nodules, butwith less specificity. For malignancies that do not usually metastasizeto the lung, the yield of thoracic CT for metastatic disease withoutmetastatic disease elsewhere, is low. However, the chest CT ismore likely to demonstrate very small lesions (< 1 cm) thatare not detected by standard chest radiography.
Positron Emission Tomography: Unlike most radiographicimaging modalities which rely on morphologic features for thedetection of disease, PET is a functional imaging technique thatrelies on the metabolic characteristics of tissue for diagnosis. Furthermore, it has a relatively high spatial resolution in comparisonto other functional nuclear medicine techniques, making it especiallyuseful for assessing small, indeterminate pulmonary lesions. It may also be useful for selecting patients for resection, whenwhole-body PET is utilized.
Magnetic Resonance Imaging: MRI has high-contrastresolution and sensitivity to flowing blood. It is especiallyuseful in assessing the extent of tumor invasion of the mediastinumand great vessels, for studying vascular lesions within the chest,and in evaluation fibrosis or atelectasis. It is, however, oflimited value in imaging lung parenchyma, and is its resolutionis further compromised by respiratory motion. An advantage ofMRI over CT is multiplanar imaging capabilities, which may beespecially helpful in the assessment of vascular structures, thechest wall, or the brachial plexus.
The choice of imaging modalities in the staging, detection, andsurveillance of cancer patients should be governed by the naturalbehavior of the primary tumor and how the results would impacton management of the disease. Such an approach should be individuallymade, relying on tumor behavior, treatment options, and utilityof the diagnostic modality. Finally, cost-effectiveness considerationswhen the techniques are utilized in the appropriate settings shouldhelp to yield a balanced treatment approach for the patient.
As an oncologist, Dr. Giantonio provides care for many patients at the end of life, which he describes as a privilege and rewarding. Read more.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Cladribine (2-CDA, Leustatin®)
Cyclophosphamide (Cytoxan®, Neosar®, Endoxan®)
Cyclosporine (Neoral®, Sandimmune®, Restasis®, Gengraf®)
Cytarabine (Cytosar-U®, Ara-C)
Irinotecan (Camptosar®, CPT-11)
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Men
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Women
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Busulfan (Myleran®, Busulfex®)
Intravesicular Mitomycin (Mutamycin®, Mitomycin-C, given into the bladder)
Mechlorethamine (Mustargen®, Nitrogen Mustard)
mechlorethamine, mustine, Mustargen®
Megestrol (Megace®, Megace-ES®)
Mercaptopurine (Purinethol®, 6-MP)
Methotrexate (Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX)
Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX
Mitomycin (Mutamycin®, Mitomycin-C)
Morphine Sulfate (Given by IV)
Morphine Sulfate (MS Contin®, Avinza®, Kadian®, Oramorph SR®)
MS Contin®, Avinza®, Kadian®, Oramorph SR®
Mutamycin®, Mitomycin-C, given into the bladder
Nitrogen mustard (mechlorethamine, mustine, Mustargen®)
Bendamustine Hydrochloride (Treanda®)
Bexarotene (Targretin®), Oral Formulation
Bexarotene Gel (Targretin® Gel Formulation)
Etoposide (Toposar®, VePesid®, Etopophos®,VP-16)
Thioguanine (6-TG, Thioguanine Tabloid®)
Toposar®, VePesid®, Etopophos®,VP-16
Trelstar LA® and Trelstar Depot®
Tretinoin (Vesanoid®, All-Trans-Retinoic Acid, ATRA)
Triptorelin (Trelstar LA® and Trelstar Depot®)

